Business
BELLUS Health Chronic Cough Webcast Taking Place Today
BELLUS Health Chronic Cough Webcast Taking Place Today Canada NewsWire LAVAL, QC...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\nBELLUS Health Chronic Cough Webcast Taking Place Today\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nLAVAL, QC, Sept. 20, 2017\n\n\n\n- BELLUS to provide BLU-5937 program update, Key Opinion Leader Dr. Jacky Smith to present on chronic cough -\n\n\n\nLAVAL, QC, Sept. 20, 2017 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, will host a chronic cough Key Opinion Leader (KOL) presentation and BLU-5937 program update today at 2:00 PM ET. \n\nTo listen to the live webcast or to ask questions during the live event, please register at the following link: https://event.webcasts.com/starthere.jsp?ei=1159556&tp_key=4a0ae58b66. An archived version of the webcast and presentation will be available on the Company's website at www.bellushealth.com following the event.\n\nThe event will feature a presentation by KOL Dr. Jacky Smith, Professor of Respiratory Medicine at the University of Manchester and Director of the NIHR South Manchester Respiratory and Allergy Clinical Research Facility. Dr. Smith will discuss the clinical presentation of chronic cough, its current unmet medical need and therapeutic options, as well as novel treatment approaches under development. \n\nDr. Denis Garceau, BELLUS Health's Senior Vice President, Drug Development, will also provide an update on the BLU-5937 program, including recent study results that show a significant reduction in cough with no taste disturbance in two separate preclinical models. In the guinea pig cough model, BLU-5937 demonstrated comparable efficacy to the current leading P2X3 antagonist, Merck & Co's Gefapixant (also named AF-219 or MK-7264). In the rat taste model, BLU-5937 did not show taste inhibition; however, consistent with clinical trial data previously presented by Merck & Co, Gefapixant did significantly impact taste.\n\nBoth Dr. Smith and Dr. Garceau will be available to answer questions at the end of their pres...